BUDAPEST, Hungary, Jan. 16 /PRNewswire/ -- RecomGenex Ltd. announced today that they have entered into a research collaboration with AstraZeneca AB to produce unique functional nuclear receptors to be used for research purposes.
Applying their proprietary RefoldAll(TM) protein renaturation technology to inclusion bodies provided by AstraZeneca, RecomGenex will determine optimal conditions needed to properly fold these complex proteins so they demonstrate full functionality. Under terms of the collaboration, resulting proteins will be owned exclusively by AstraZeneca.
"This collaboration allows us to demonstrate the power of our RefoldAll(tm) technology in solving difficult protein refolding problems experienced in the expression of complex proteins," said Geza Ambrus-Aikelin, CEO of RecomGenex.
About RecomGenex, Ltd.:
RecomGenex is subsidiary of ComGenex, an integrated discovery service provider for the pharmaceutical and biotechnology industries. RecomGenex offers proprietary protein expression services including refolding, while ComGenex offers proprietary services and methods in the area of chemistry, instrumentation, high-throughput analytics, informatics and ADME. The company has a proven track record of successful collaborations with major pharmaceutical, chemical and biotechnology companies. Commercially, RecomGenex offers clients 'off the shelf' services and collaborative development in the field of protein research.
CONTACT: Geza Ambrus-Aikelin, Chief Executive Officer, +36-1-214-2306,firstname.lastname@example.org, or William P. Heilman, PhD, Head of BusinessDevelopment, +1-732-438-8001, email@example.com, both ofRecomGenex Ltd.